Table 1.
Comparisons of differences between patients with community-acquired K. pneumoniae bacteremia and control group
| |
Community-acquired
K. pneumoniae
bacteremia |
|
|
|
|
|---|---|---|---|---|---|
|
Variable |
Invasive syndrome (%) |
|
|
|
|
| Yes (n = 76) | No (n = 332) | p value | Control (%) (n = 76) | p value + | |
| Hypermucoviscosity phenotype of K. pneumoniae |
69 (90.8) |
78 (23.5) |
< 0.01* |
|
|
| Male |
40 (52.6) |
150 (45.2) |
0.25 |
40 (52.6) |
0.99 |
| Age ≥ 60 yrs |
39 (51.3) |
128 (38.6) |
0.05 |
39 (51.3) |
0.99 |
| Diabetes mellitus (DM) |
41 (53.9) |
134 (40.4) |
0.04 |
25 (32.9) |
0.01 |
| DM with poor glycemic control (HbA1c ≥ 9%) |
32 (42.1) |
75 (22.6) |
< 0.01* |
17 (22.4) |
0.02 |
| Cardiovascular diseases |
17 (22.4) |
65 (19.6) |
0.69 |
21 (27.6) |
0.57 |
| Liver cirrhosis |
5 (6.6) |
45 (13.6) |
0.12 |
10 (13.2) |
0.28 |
| Chronic renal failure |
10 (13.2) |
35 (10.5) |
0.54 |
18 (23.7) |
0.14 |
| Malignancy |
4 (5.3) |
33 (9.9) |
0.27 |
18 (23.7) |
< 0.01 |
| Biliary tract diseases |
2 (2.6) |
20 (6.0) |
0.39 |
8 (10.5) |
0.10 |
| Absence of underlying diseases |
12 (15.8) |
44 (13.3) |
0.69 |
9 (11.8) |
0.64 |
| Therapy in the month prior to the infection |
|
|
|
|
|
| Proton-pump inhibitors |
8 (10.5) |
24 (7.2) |
0.47 |
15 (19.7) |
0.17 |
| Aspirin |
2 (2.6) |
56 (16.9) |
< 0.01* |
8 (10.5) |
0.10 |
| Antibiotics | 5 (6.6) | 28 (8.4) | 0.76 | 12 (15.8) | 0.12 |
+ Age-matched analysis (K. pneumoniae invasive syndrome vs. control group).
*Results of multivariate analysis indicated that community-acquired K. pneumoniae bacteremic patients who were infected by strains expressing the hypermucoviscosity phenotype (odds ratio [OR], 31.07; 95% confidence interval [CI], 13.55-71.22; p < 0.01) and diabetic patients with poor glycemic control (OR, 2.46; 95% CI, 1.27-4.77; p < 0.01) were at increased risk, whereas those who had recent therapy with aspirin (OR, 0.17; 95% CI, 0.04-0.79; p = 0.02) were at lower risk of acquiring K. pneumoniae-associated invasive syndrome.